Pain Relief (PR) Notes to Readers

Size: px
Start display at page:

Download "Pain Relief (PR) Notes to Readers"

Transcription

1 Pain (PR) Questionnaire Supplement to the Study Data Tabulation Model Implementation Guide for Human Clinical Trials Prepared by CDISC and Analgesic Clinical Trial Translations, Innovations, Opportunities, and Networks (ACTTION) Notes to Readers This implementation guide is intended to be used with other CDISC User Guides for specific Therapeutic/Disease Areas and follows the CDISC Study Data Tabulation Model Implementation Guide for Human Clinical trials Clinical Data Interchange Standards Consortium, Inc. All rights reserved Page 1

2 Revision History Date Version Summary of Changes Pain (included in the NV domain for public review) Pain 2012 Clinical Data Interchange Standards Consortium, Inc. All rights reserved Page 2

3 1 Introduction This document describes the CDISC implementation of the Pain questionnaire, a standard public domain questionnaire administered on a CRF that is typically used in clinical trials to measure pain response. Please refer to the CDISC Pain Standards User Guide ( for information on developing this data standard by the sponsor, Analgesic Clinical Trial Translations, Innovations, Opportunities, and Networks (ACTTION) and their working group, STandardized ANalgesic DAtabase for Research, Discovery, and Submissions (STANDARDS). The Pain concept preceded the CDISC CDASH CRF standards and has no standard CRF, based on its public domain status. CDASH standard CRFs may be developed in the future. The representation of data collected for this questionnaire is based on the Study Data Tabulation Model Implementation Guide (SDTMIG) QS domain table (SDTMIG), which can be found at the CDISC website at These implementation details for this specific questionnaire are meant to be used in conjunction with the SDTMIG, but are recorded separately since this questionnaire may be used in many different therapeutic area implementations. All questionnaire documentation can be found on the CDISC web site ( The CDISC Intellectual Property Policy can be found in the ABOUT CDISC/Bylaws & Policies section of the web site. 1.1 Representations and Warranties, Limitations of Liability, and Disclaimers This document is a supplement to the Study Data Tabulation Model Implementation Guide for Human Clinical Trials and is covered under Appendix F of that document, which describes representations, warranties, limitations of liability, and disclaimers. Please see Appendix F of the SDTMIG for a complete version of this material Clinical Data Interchange Standards Consortium, Inc. All rights reserved Page 3

4 2 Copyright Status This instrument is in the public domain. CDISC has included the general Pain concepts as part of CDISC Data Standards. This means that CDISC developed QSCAT, QSTESTCD and QSTEST for the questions based on the actual question text on the questionnaire. There may be many versions of this questionnaire in the public domain. CDISC has chosen to use this version as the data standard. The CDISC documentation of this instrument consists of: (1) controlled terminology, (2) standard database structure with examples and (3) case report forms annotated with the CDISC SDTMIG submission values are not available, due to the general Pain concepts not having a published standard CRF. Note: CDISC controlled terminology is maintained by NCI EVS. The most recent version should be accessed through the CDISC website. ( CDISC has developed this documentation at no cost to users of the instrument. Reference: Handbook of Pain Assessment, Third Edition [Hardcover] Chapter 2 - Self-Report Scales and Procedures for Assessing Pain in Adults: Dennis C. Turk PhD (Editor), Ronald Melzack PhD (Editor) This definitive clinical reference comprehensively reviews the most advanced methods for assessing the person in pain. The field's leading authority s present essential information and tools for evaluating psychosocial, behavioral, situational, and medical factors in patients' subjective experience, functional impairment, and response to treatment. Empirically supported instruments and procedures are detailed, including self-report measures, observational techniques, psychophysiological measures, and more. Best-practice recommendations are provided for assessing the most prevalent pain syndromes and for working with children, older adults, and people with communication difficulties. The book also weighs in on the limitations of existing methods and identifies key directions for future research. CDISC acknowledges Dennis Turk and Ronald Melzack for inclusion of the Pain concepts as part of the CDISC SDTM Data standards Clinical Data Interchange Standards Consortium, Inc. All rights reserved Page 4

5 3 The QS Domain Model 3.1 Assumptions for the Pain Questionnaire Domain Model All assumptions for the QS domain from the SDTMIG apply for this supplemental implementation guide including those referenced in the CDISC notes. Additionally, the following assumptions apply to Pain : 1. The questions relevant to measurement of Pain are in the public domain and routinely used in a variety of Pain/Analgesic condition studies. The Pain measures are a rating of the relief of pain at specified time points. Visual analog or numeric rating scales used within a questionnaire with a range of text and numeric values are indicated in the SUPPQS domain with: QNAM=RNGTXTLO QNAM=RNGTXTHI QNAM=RNGVALLO QNAM=RNGVALHI By storing this information in SUPPQS, it is available for interpretation purposes. The SDS QS Team is researching alternative methods to handle this data, but until a new method is identified, this will be the agreed approach. Pain is usually measured in a verbal rating scale with a categorical list of text and numeric values that are indicated in the SUPPQS domain as described above. For a verbal scale, the subject selects a descriptive phrase. Since the design of Pain/Analgesic studies is continually evolving, often using different numeric values for the same text values across drug projects and studies, the STANDARDS Working Group realized that further terminology standardization in the Pain Therapeutic Area will be needed on an ongoing basis. Such additional future terminology standards, where applicable, may be addressed by ACTTION in subsequent versions. CDISC and the ACTTION working group have suggested draft terminology for these pain scales. At the current time, standardization of these terms for data pooling will need to be performed in analysis datasets using the CDISC Analysis Data Model (ADaM) and the Statistical Analysis Plan (SAP). 2. Pain assessments include a variety of types of measurements beyond relief in general. This is normally specified in the question being asked as Rate your pain relief. Individual Pain test codes and test names are defined for each of these Pain questions. Pain Average Pain Least Pain Worst Pain 2012 Clinical Data Interchange Standards Consortium, Inc. All rights reserved Page 5

6 Minimum Pain Maximum Pain 3. The following Pain measures are also used in specific pain condition studies and are illustrated in the example below. This is normally specified in individual questions. Individual Pain test codes and test names are defined for each of these pain relief questions. Starting Pain at Least 1/2 Gone Time to Perceptible Pain Was there Perceptible Pain Time to Meaningful Pain Was there Meaningful Pain 4. The location of pain relief is populated in QSLOC with CDISC Location Terminology indicating the anatomical location when specified in a study. If multiple pain relief locations are specified separately at the same time point, separate records will be created for each anatomical location in order to enable analysis for each location. When a study is conducted for a specific type of overall pain (.ex Fibromyalgia, Diabetic Neuropathy, etc.), the Medical History MHTERM for the MHCAT=PRIMARY DIAGNOSIS will indicate the type and time reference of pain historically observed. Refer to the Pain Standards User Guide ( for a data example of this MH record. If this is not captured, the Trial Summary domain would contain an indication parameter to define the pain being investigated in the study. 1. Pain is relief at the time the question is asked. All the other test names above imply a period of time. For example, Least Pain in the last week could easily have a different value from Least Pain in the last year. This period of time should be clear in the data collection and, if it is, should be represented in the SDTM dataset as described below. The time period of evaluation of Pain is populated in the QSEVLINT field in ISO 8601 format when the evaluation interval can be precisely described as a duration as shown in examples a-c below. Specific points in time should use the QSDTC field as shown in example d. In cases where the evaluation interval cannot be precisely described as an ISO 8601 duration, the evaluation period should be represented using the Supplemental Qualifier EVLINTTX, as shown in examples e-g. In cases that are related to protocol-specified points in time, the QSTPT variable may be used as in example h. a. over last 24 hours QSEVLINT = -PT24H b. over last hour QSEVLINT = -PT1H c. over last week QSEVLINT = -P1W 2012 Clinical Data Interchange Standards Consortium, Inc. All rights reserved Page 6

7 d. right now QNAM=EVLINTTX QVAL= right now e. over the last night s sleep QNAM=EVLINTTX QVAL= Over last Night s Sleep f. Starting Pain is measured from the beginning of treatment QNAM=EVLINTTX QVAL= Pain from beginning of treatment g. since last medication: - QNAM=EVLINTTX QVAL= Since last medication h. At use of rescue medication this type of CRF is usually supplied at non-scheduled time point when rescue medication is administered to assist in relieving pain. The CDISC visit field is populated with VISIT= study design VISIT value QSTPT= Rescue Medication as a planned time point 5. Frequency/Timing of Pain measures captured in a study is normally included in the protocol s table of time and events (e.g., Hourly, Multiple times per day, periodic, etc.) For example, a rating of pain relief in the past 24 hours could be administered every day or once each week, and a rating of average pain relief in the past 7 days could be administered every week or once a month. The CDISC Trial Design model represents information about the protocol as parameters in the Trial Summary domain, and a terminology request is being submitted for the TSPARMCD=RATNGFRQ and TSPARM=Frequency of Rating Capture to address this need. CDISC will announce an alternative if one is determined to be necessary upon further investigation. 6. Activity during Pain measurements is populated in SUPPQS with QNAM=MOVETYP and QLABEL = values provided below. A. Not specified B. At rest C. With Movement 7. The evaluator of the questionnaire is stored in QSEVAL and for the Pain the Subject provides the evaluation of pain relief. 8. Terminology A. Requests for controlled terminology for the QSCAT, QSTESTCD, QSTEST and QSMETHOD variables are being submitted through the CDISC controlled terminology process. Controlled terminology is still under development for the Pain data standards, thus some values in the examples are not CDISC controlled terms. Verify demonstrated terminology against current standards before adopting it. B. Controlled terminology code lists are being submitted for the VERBAL RATING SCALE 6-POINT value lists as displayed in section 4. C. The specific mapping strategy for Pain using standard QS fields is described in Section 4: Mapping Strategy for the following required fields Clinical Data Interchange Standards Consortium, Inc. All rights reserved Page 7

8 Section 4 provides guidance on how the result and category variables in the QS domain need to be populated for a questionnaire. (ex. QSORRES, QSORRESU, QSSTRESC, QSSTRESN, QSSTRESU, QSCAT and QSMETHOD) If a result variable is not included in the table for a questionnaire, it should not be populated. D. SUPPQS is used for additional data standardization with those data items listed in the Appendix C: Supplemental Qualifiers. 3.2 Examples for Pain Domain Model Example 1: 5-Point Verbal Rating Scale This example shows data from one subject collected at three visits for a Back Pain 5-Point Rating Scale questionnaire evaluated over the past 24 hours. The example uses standard controlled terminology for QSTESTCD, QSTEST, QSCAT, QSMETHOD and QSLOC for the Pain scale. QSSTRESN will be set to the standard numeric value and then converted into QSSTRESC. SUPPQS is populated with the data range text and numeric values. Rows 1-3: qs.xpt Represent 3 visit values of Back Pain ratings for USUBJID= from a Pain 5-Point Rating Scale Form. All original results are represented in QSORRES, which is then transformed into a Standard Numeric rating QSSTRESN, which is then also copied to a standard character value in QSSTRESC. Row STUDYID DOMAIN USUBJID QSSEQ QSTESTCD QSTEST QSCAT QSORRES QSSTRESC QSSTRESN QSMETHOD 1 STUDYX QS PR01 - Pain A LITTLE VERBAL RATING SCALE 5-1 PR POINT 2 STUDYX QS PR01 - Pain VERBAL RATING SCALE 5-2 PR01001 SOME 2 2 POINT 3 STUDYX QS PR01 - Pain A LOT OF VERBAL RATING SCALE 5-3 PR POINT Row QSLOC QSEVAL VISITNUM QSDTC QSDY QSEVLINT 1 (cont d) BACK SUBJECT PT24H 2 (cont d) BACK SUBJECT PT24H 3 (cont d) BACK SUBJECT PT24H The data range text and numeric values for data collection values need to be populated in SUPPQS. These data range values for Pain are mapped to SUPPQS domain as follows. The standard terminology for QNAM and QLABEL are listed below. suppqs.xpt STUDYID RDOMAIN USUBJID IDVAR IDVARVAL QNAM QLABEL QVAL QORIG QEVAL 2012 Clinical Data Interchange Standards Consortium, Inc. All rights reserved Page 8

9 STUDYX QS QSSEQ 1 RNGTXTLO Range Text Lo NO CRF STUDYX QS QSSEQ 1 RNGTXTHI Range Text Hi COMPLETE CRF STUDYX QS QSSEQ 1 RNGVALLO Range Value Lo 0 CRF STUDYX QS QSSEQ 1 RNGVALHI Range Value HI 4 CRF STUDYX QS QSSEQ 2 RNGTXTLO Range Text Lo NO CRF STUDYX QS QSSEQ 2 RNGTXTHI Range Text Hi COMPLETE CRF STUDYX QS QSSEQ 2 RNGVALLO Range Value Lo 0 CRF STUDYX QS QSSEQ 2 RNGVALHI Range Value HI 4 CRF STUDYX QS QSSEQ 3 RNGTXTLO Range Text Lo NO CRF STUDYX QS QSSEQ 3 RNGTXTHI Range Text Hi COMPLETE CRF STUDYX QS QSSEQ 3 RNGVALLO Range Value Lo 0 CRF STUDYX QS QSSEQ 3 RNGVALHI Range Value HI 4 CRF Example 2: 5-Point Verbal Rating Scale This example shows data from one subject collected at three visits for a Worst Back Pain 5-Point Verbal Rating Scale questionnaire evaluated over the past 24 hours. The example uses standard controlled terminology for QSTESTCD, QSTEST, QSCAT, QSMETHOD and QSLOC for the Pain scale. QSSTRESN will be set to the standard numeric value and then converted into QSSTRESC. Rows 1-3: Represent 3 visit values of Worst Back Pain for USUBJID= from a Pain 5-Point Verbal Rating Scale Form. All original results are represented in QSORRES, which is then transformed into a Standard Numeric rating QSSTRESN, which is then also copied to a standard character value in QSSTRESC. SUPPQS is populated with the data range text and numeric values. qs.xpt Row STUDYID DOMAIN USUBJID QSSEQ QSTESTCD QSTEST QSCAT QSORRES QSSTRESC QSSTRESN QSMETHOD 1 STUDYX QS PR01 - Worst Pain VERBAL RATING SCALE 5-1 PR01006 A LITTLE 1 1 POINT 2 STUDYX QS PR01 - Worst Pain VERBAL RATING SCALE 5-2 PR01006 SOME 2 2 POINT 3 STUDYX QS PR01 - Worst Pain COMPLETE VERBAL RATING SCALE 5-3 PR POINT Row QSLOC QSEVAL VISITNUM QSDTC QSDY QSEVLINT 1 (cont d) BACK SUBJECT PT0H 2 (cont d) BACK SUBJECT PT24H 3 (cont d) BACK SUBJECT PT24H The data range text and numeric values for data collection values need to be populated in SUPPQS. These data range values for Pain are mapped to SUPPQS domain as follows. The standard terminology for QNAM and QLABEL are listed below Clinical Data Interchange Standards Consortium, Inc. All rights reserved Page 9

10 suppqs.xpt STUDYID RDOMAIN USUBJID IDVAR IDVARVAL QNAM QLABEL QVAL QORIG QEVAL STUDYX QS QSSEQ 1 RNGTXTLO Range Text Lo NO CRF STUDYX QS QSSEQ 1 RNGTXTHI Range Text Hi COMPLETE CRF STUDYX QS QSSEQ 1 RNGVALLO Range Value Lo 0 CRF STUDYX QS QSSEQ 1 RNGVALHI Range Value HI 4 CRF STUDYX QS QSSEQ 2 RNGTXTLO Range Text Lo NO CRF STUDYX QS QSSEQ 2 RNGTXTHI Range Text Hi COMPLETE CRF STUDYX QS QSSEQ 2 RNGVALLO Range Value Lo 0 CRF STUDYX QS QSSEQ 2 RNGVALHI Range Value HI 4 CRF STUDYX QS QSSEQ 3 RNGTXTLO Range Text Lo NO CRF STUDYX QS QSSEQ 3 RNGTXTHI Range Text Hi COMPLETE CRF STUDYX QS QSSEQ 3 RNGVALLO Range Value Lo 0 CRF STUDYX QS QSSEQ 3 RNGVALHI Range Value HI 4 CRF Example 3: Pain Rating and General Pain Questions collected in a Surgical Condition Study This example is based on a legacy sponsor specific CRF, in which the Pain Intensity measure is taken prior to dosing and then at hour readings. The Pain results are also obtained at specific hour time points for Pain and Starting Pain ½ Gone. At the end of the Pain capture, the following questions were asked for Was there meaningful pain relief, Time to meaningful pain relief, Was there perceptible pain relief, and the Time to perceptible pain relief. This example shows data from one subject collected with data collected at hour time points indicated with QSTPT=Pre-Treatment, 1H, 2H, 4H, & 6H collecting the following fields: 1. Pain 5-Point Verbal Rating Scale 2. Starting Pain at Least ½ Gone 3. Time to Perceptible Pain 4. Was there Perceptible Pain 5. Time to Meaningful Pain 6. Was there Meaningful Pain 2012 Clinical Data Interchange Standards Consortium, Inc. All rights reserved Page 10

11 The example uses standard controlled terminology for QSTESTCD, QSTEST, QSCAT, QSMETHOD and QSLOC for the Pain scale. QSSTRESN will be set to the standard numeric value and then converted into QSSTRESC for the Verbal Rating Scale 5-Point. SUPPQS is populated with the data range text and numeric values. Rows 1-12: qs.xpt Represent hour specific time point collection of Pain and General Pain questions for USUBJID=. All original results are represented in QSORRES, which is then transformed into a standard numeric rating QSSTRESN for the verbal rating scale 5-point, which is then also copied to a standard character value in QSSTRESC. Row STUDYID DOMAIN USUBJID QSSEQ QSTESTCD QSTEST QSCAT QSORRES QSORRESU QSSTRESC QSSTRESN QSSTRESU QSMETHOD VERBAL PR01 - Pain 1 STUDYX QS 1 PR01001 NO 0 0 RATING SCALE 5-POINT 2 STUDYX QS 3 STUDYX QS 4 STUDYX QS 5 STUDYX QS 6 STUDYX QS 7 STUDYX QS 8 STUDYX QS 9 STUDYX QS 10 STUDYX QS 11 STUDYX QS 12 STUDYX QS 2 PR PR PR PR PR PR PR PR PR PR PR01011 PR01 - Starting Pain at Least 1/2 Gone PR01 - Pain PR01 - Starting Pain at Least 1/2 Gone PR01 - Pain PR01 - Starting Pain at Least 1/2 Gone PR01 - Pain PR01 - Starting Pain at Least 1/2 Gone PR01 - Was there Perceptible Pain PR01 - Time to Perceptible Pain PR01 - Was there Meaningful Pain PR01 - Time to Meaningful N N NO 0 0 N N SOME Y Y A LOT OF Y Y Y Y MIN MIN Y Y 360 MIN MIN VERBAL RATING SCALE 5-POINT VERBAL RATING SCALE 5-POINT VERBAL RATING SCALE 5-POINT 2012 Clinical Data Interchange Standards Consortium, Inc. All rights reserved Page 11

12 Row STUDYID DOMAIN USUBJID QSSEQ QSTESTCD QSTEST QSCAT QSORRES QSORRESU QSSTRESC QSSTRESN QSSTRESU QSMETHOD Pain Row QSLOC QSEVAL VISITNUM QSDTC QSDY QSTPT QSTPTREF 1 (cont d) BACK SUBJECT T13:00 1 P1H Initial Dose 2 (cont d) BACK SUBJECT T13:00 1 P1H Initial Dose 3 (cont d) BACK SUBJECT T14:00 1 P2H Initial Dose 4 (cont d) BACK SUBJECT T14:00 1 P2H Initial Dose 5 (cont d) BACK SUBJECT T16:00 1 P4H Initial Dose 6 (cont d) BACK SUBJECT T16:00 1 P4H Initial Dose 7 (cont d) BACK SUBJECT T18:00 1 P6H Initial Dose 8 (cont d) BACK SUBJECT T18:00 1 P6H Initial Dose 9 (cont d) BACK SUBJECT T18:00 1 P6H Initial Dose 10 (cont d) BACK SUBJECT T18:00 1 P6H Initial Dose 11 (cont d) BACK SUBJECT T18:00 1 P6H Initial Dose 12 (cont d) BACK SUBJECT T18:00 1 P6H Initial Dose The data range text and numeric values for data collection values need to be populated in SUPPQS. These data range values for Pain are mapped to SUPPQS domain as follows. The standard terminology for QNAM and QLABEL are listed below. suppqs.xpt STUDYID RDOMAIN USUBJID IDVAR IDVARVAL QNAM QLABEL QVAL QORIG QEVAL STUDYX QS QSSEQ 1 RNGTXTLO Range Text Lo NO CRF STUDYX QS QSSEQ 1 RNGTXTHI Range Text Hi COMPLETE CRF STUDYX QS QSSEQ 1 RNGVALLO Range Value Lo 0 CRF STUDYX QS QSSEQ 1 RNGVALHI Range Value HI 4 CRF STUDYX QS QSSEQ 3 RNGTXTLO Range Text Lo NO CRF STUDYX QS QSSEQ 3 RNGTXTHI Range Text Hi COMPLETE CRF STUDYX QS QSSEQ 3 RNGVALLO Range Value Lo 0 CRF STUDYX QS QSSEQ 3 RNGVALHI Range Value HI 4 CRF STUDYX QS QSSEQ 5 RNGTXTLO Range Text Lo NO CRF STUDYX QS QSSEQ 5 RNGTXTHI Range Text Hi COMPLETE CRF STUDYX QS QSSEQ 5 RNGVALLO Range Value Lo 0 CRF STUDYX QS QSSEQ 5 RNGVALHI Range Value HI 4 CRF STUDYX QS QSSEQ 7 RNGTXTLO Range Text Lo NO CRF STUDYX QS QSSEQ 7 RNGTXTHI Range Text Hi COMPLETE CRF STUDYX QS QSSEQ 7 RNGVALLO Range Value Lo 0 CRF STUDYX QS QSSEQ 7 RNGVALHI Range Value HI 4 CRF 2012 Clinical Data Interchange Standards Consortium, Inc. All rights reserved Page 12

13 4 SDTM Mapping Strategy Pain specific mapping strategy: This section is used to understand the alignment of the questionnaire to the SDTM QS domain. It also provides guidance on how the result variables (QSORRES, QSORRESU, QSSTRESC, QSSTRESN, and QSSTRESU) should be populated for each questionnaire. If a result variable is not included in the table for a questionnaire, it should not be populated. QSCAT Pain QSTESTCD/QSTEST Proposed Terminology QSTESTCD QSTEST PR01001 PR01 - Pain PR01002 PR01 - Average Pain PR01003 PR01 - Pain Minimum PR01004 PR01 - Pain Maximum PR01005 PR01 - Pain Least PR01006 PR01 - Pain Worst PR01007 PR01 - Starting Pain at Least 1/2 Gone PR01008 PR01 - Was there Perceptible Pain PR01009 PR01 - Time to Perceptible Pain PR01010 PR01 - Was there Meaningful Pain PR01011 PR01 - Time to Meaningful Pain QSMETHOD VERBAL RATING SCALE 5-POINT SUPPQS QVAL value standardization for data range text values QNAM QVAL RNGTXTLO NO RNGTXTHI COMPLETE QSCAT= QSMETHOD = VERBAL RATING SCALE 5-POINT QSTEST = Pain QSORRES QSSTRESC QSSTRESN NO 0 0 A LITTLE 1 1 SOME Clinical Data Interchange Standards Consortium, Inc. All rights reserved Page 13

14 A LOT OF 3 3 COMPLETE Clinical Data Interchange Standards Consortium, Inc. All rights reserved Page 14

15 SUPPLEMENTAL QUALIFIERS NAME CODES The following table contains an additional standard name codes for use in the Supplemental Qualifiers for Questionnaires (SUPPQS) special-purpose datasets... QNAM QLABEL Applicable Domains RNGTXTLO Range Text Lo QS RNGTXTHI Range Text Hi QS RNGVALLO Range Value Lo QS RNGVALHI Range Value Hi QS EVLINTTX Evaluation Time Reference Description QS MOVETYP Movement QS End of Document 2012 Clinical Data Interchange Standards Consortium, Inc. All rights reserved Page 15

Neuropathic Pain Scale (NPS)

Neuropathic Pain Scale (NPS) Neuropathic Pain Scale (NPS) Questionnaire Supplement to the Study Data Tabulation Model Implementation Guide for Human Clinical Trials Prepared by Business & Decision Life Sciences and the CDISC Questionnaire

More information

Short-Form McGill Pain Questionniare-2 (SHORT-FORM MPQ-2)

Short-Form McGill Pain Questionniare-2 (SHORT-FORM MPQ-2) Short-Form McGill Pain Questionniare-2 ( ) Questionnaire Supplement to the Study Data Tabulation Model Implementation Guide for Human Clinical Trials Prepared by CDISC and Analgesic Clinical Trial Translations,

More information

Columbia-Suicide Severity Rating Scale Baseline (C-SSRS BASELINE)

Columbia-Suicide Severity Rating Scale Baseline (C-SSRS BASELINE) Columbia-Suicide Severity Rating Scale Baseline ( ) Questionnaire Supplement to the Study Data Tabulation Model Implementation Guide for Human Clinical Trials Prepared by CDISC and Analgesic Clinical Trial

More information

Clinical Global Impression (CGI)

Clinical Global Impression (CGI) Clinical Global Impression (CGI) Questionnaire Supplement to the Study Data Tabulation Model Implementation Guide for Human Clinical Trials Prepared by CDISC and Analgesic Clinical Trial Translations,

More information

Disability Assessment for Dementia (DAD)

Disability Assessment for Dementia (DAD) Disability Assessment for Dementia (DAD) Questionnaire Supplement to the Study Data Tabulation Model Implementation Guide for Human Clinical Trials Prepared by CAMD AD v1.1 Team and the CDISC Questionnaire

More information

Hospital Anxiety and Depression Scale (HADS)

Hospital Anxiety and Depression Scale (HADS) Hospital Anxiety and Depression Scale (HADS) Questionnaire Supplement to the Study Data Tabulation Model Implementation Guide for Human Clinical Trials Prepared by Business & Decision Life Sciences and

More information

Brief Psychiatric Rating Scale-Anchored (BPRS-A)

Brief Psychiatric Rating Scale-Anchored (BPRS-A) Brief Psychiatric Rating Scale-Anchored (BPRS-A) Questionnaire Supplement to the Study Data Tabulation Model Implementation Guide for Human Clinical Trials Prepared by CDISC Questionnaire Sub-team Notes

More information

Michigan Neuropathy Screening Instrument (MNSI)

Michigan Neuropathy Screening Instrument (MNSI) Michigan Neuropathy Screening Instrument () Questionnaire Supplement to the Study Data Tabulation Model Implementation Guide for Human Clinical Trials Prepared by CDISC and Analgesic Clinical Trial Translations,

More information

Epworth Sleepiness Scale (ESS)

Epworth Sleepiness Scale (ESS) Epworth Sleepiness Scale (ESS) Questionnaire Supplement to the Study Data Tabulation Model Implementation Guide for Human Clinical Trials Prepared by CDISC Questionnaires Sub-team Notes to Readers This

More information

Brief Psychiatric Rating Scale-Anchored (BPRS-A)

Brief Psychiatric Rating Scale-Anchored (BPRS-A) Brief Psychiatric Rating Scale-Anchored (BPRS-A) Questionnaire Supplement to the Study Data Tabulation Model Implementation Guide for Human Clinical Trials Prepared by CDISC Questionnaire Sub-team Notes

More information

Modified Hachinski Ischemic Scale: NACC Version (MHIS-NACC) v.1.0

Modified Hachinski Ischemic Scale: NACC Version (MHIS-NACC) v.1.0 Modified Hachinski Ischemic Scale: NACC Version (MHIS-NACC) v.1.0 Questionnaire Supplement to the Study Data Tabulation Model Implementation Guide for Human Clinical Trials Prepared by CAMD AD v2.0 Team

More information

Columbia-Suicide Severity Rating Scale Baseline (C-SSRS BASELINE)

Columbia-Suicide Severity Rating Scale Baseline (C-SSRS BASELINE) Columbia-Suicide Severity Rating Scale Baseline ( ) Questionnaire Supplement to the Study Data Tabulation Model Implementation Guide for Human Clinical Trials Prepared by CDISC and Analgesic Clinical Trial

More information

Columbia-Suicide Severity Rating Scale Baseline (C-SSRS BASELINE)

Columbia-Suicide Severity Rating Scale Baseline (C-SSRS BASELINE) Columbia-Suicide Severity Rating Scale Baseline ( ) Questionnaire Supplement to the Study Data Tabulation Model Implementation Guide for Human Clinical Trials Prepared by CDISC and Analgesic Clinical Trial

More information

Hamilton Depression Rating Scale 17-Item (HAMD 17)

Hamilton Depression Rating Scale 17-Item (HAMD 17) Hamilton Depression Rating Scale -Item ( ) Questionnaire Supplement to the Study Data Tabulation Model Implementation Guide for Human Clinical Trials Prepared by CDISC and Analgesic Clinical Trial Translations,

More information

Barnes Akathisia Rating Scale (BARS)

Barnes Akathisia Rating Scale (BARS) Barnes Akathisia Rating Scale () Questionnaire Supplement to the Study Data Tabulation Model Implementation Guide for Human Clinical Trials Prepared by CDISC Questionnaire Sub-team Notes to Readers This

More information

Timed Up and Go (TUG)

Timed Up and Go (TUG) Timed Up and Go (TUG) Functional Test Supplement to the Study Data Tabulation Model Implementation Guide for Human Clinical Trials Prepared by Multiple Sclerosis Outcomes Assessment Consortium and the

More information

Unified Parkinson's Disease Rating Scale UPDRS

Unified Parkinson's Disease Rating Scale UPDRS Unified Parkinson's Disease Rating Scale Questionnaire Supplement to the Study Data Tabulation Model Implementation Guide for Human Clinical Trials Prepared by CDISC and National Institute of Neurological

More information

Unified Parkinson's Disease Rating Scale UPDRS

Unified Parkinson's Disease Rating Scale UPDRS Unified Parkinson's Disease Rating Scale Questionnaire Supplement to the Study Data Tabulation Model Implementation Guide for Human Clinical Trials Prepared by CDISC and National Institute of Neurological

More information

Alzheimer s Disease-specific Therapeutic Area Supplement to the Study Data Tabulation Model User Guide

Alzheimer s Disease-specific Therapeutic Area Supplement to the Study Data Tabulation Model User Guide CDISC Alzheimer s disease SDTM User Guide (Version 1.0) Alzheimer s Disease-specific Therapeutic Area Supplement to the Study Data Tabulation Model User Guide Prepared by the Coalition Against Major Diseases

More information

PharmaSUG Paper DS04

PharmaSUG Paper DS04 PharmaSUG2014 - Paper DS04 Considerations in the Submission of Exposure Data in SDTM-Based Datasets Fred Wood, Accenture Life Sciences, Wayne, PA Jerry Salyers, Accenture Life Sciences, Wayne, PA Richard

More information

CDISC BrCa TAUG & Oncology Information Session

CDISC BrCa TAUG & Oncology Information Session 1 15 September 2016 CDISC BrCa TAUG & Oncology Information Session Barrie Nelson @ DCDISC 2 24 February 2016 10:00-11:30am CST CDISC Oncology Information Session Rhonda Facile, Ann White, John Owen, Diane

More information

PharmaSUG Paper DS12

PharmaSUG Paper DS12 PharmaSUG 2017 - Paper DS12 Considerations and Conventions in the Submission of the SDTM Tumor and Response Domains Jerry Salyers, Accenture Accelerated R&D Services, Berwyn, PA Fred Wood, Accenture Accelerated

More information

Let s Create Standard Value Level Metadata

Let s Create Standard Value Level Metadata PRA Health Sciences PhUSE US Connect 2019 Paper DS12 February 27, 2019 David Fielding Value Level Metadata Value Level Metadata is an important part of the Define-XML that allows us to explain our study

More information

Therapeutic Area User Guide Cardiovascular V1.0 Public Review Webinar April 3, 2014

Therapeutic Area User Guide Cardiovascular V1.0 Public Review Webinar April 3, 2014 Therapeutic Area User Guide Cardiovascular V1.0 Public Review Webinar April 3, 2014 1 Therapeutic Area User Guide CV V1.0 Public Review Webinar April 3, 2014 James Tcheng, MD, FACC, DCRI Steve Kopko, CDISC,

More information

Project Charter. Template v2 June 3, February 25, Name of Project: Prostate Cancer (PrCa) Therapeutic Area Data Standards

Project Charter. Template v2 June 3, February 25, Name of Project: Prostate Cancer (PrCa) Therapeutic Area Data Standards Project Charter Template v2 June 3, 2015 Name of Project: Prostate Cancer (PrCa) Therapeutic Area Data Standards February 25, 2016 Project Manager: John Owen 1. Scope of Prostate Cancer Therapeutic Area

More information

SDTMIG v3.3 Batch 2 Upcoming Public Review. Presented by Fred Wood

SDTMIG v3.3 Batch 2 Upcoming Public Review. Presented by Fred Wood 1 SDTMIG v3.3 Batch 2 Upcoming Public Review Presented by Fred Wood 2 SDTMIG v3.3 Batch 2? What This package constitutes Batch 2 for the planned SDTMIG v3.3. It is planned to be available for a public

More information

Intervention ML: Mapping of Meal data. Rahul Loharkar, inventiv Health Clinical, Pune, India Sandeep Sawant, inventiv Health Clinical, Mumbai, India

Intervention ML: Mapping of Meal data. Rahul Loharkar, inventiv Health Clinical, Pune, India Sandeep Sawant, inventiv Health Clinical, Mumbai, India Paper DS06 Intervention ML: Mapping of Meal data. Rahul Loharkar, inventiv Health Clinical, Pune, India Sandeep Sawant, inventiv Health Clinical, Mumbai, India ABSTRACT The focus of most bioavailability/bioequivalence

More information

Jerry Salyers, Accenture Accelerated R&D Services Fred Wood, Accenture Accelerated R&D Services. PhUSE 2017 Edinburgh, Scotland Paper #DS05

Jerry Salyers, Accenture Accelerated R&D Services Fred Wood, Accenture Accelerated R&D Services. PhUSE 2017 Edinburgh, Scotland Paper #DS05 Jerry Salyers, Accenture Accelerated R&D Services Fred Wood, Accenture Accelerated R&D Services PhUSE 2017 Paper #DS05 } Review of Tumor domains and representative CRFs Ø TU (Tumor Identification) Ø TR

More information

How to manage changes to CDISC standards at Novo Nordisk. PhUSE EU Connect 2018 Sune Dandanell and Mikkel Traun

How to manage changes to CDISC standards at Novo Nordisk. PhUSE EU Connect 2018 Sune Dandanell and Mikkel Traun How to manage changes to CDISC standards at Novo Nordisk PhUSE EU Connect 2018 Sune Dandanell and Mikkel Traun How to manage changes to CDISC standards at Novo Nordisk 06-Nov-2018 2 How to manage changes

More information

CDISC - Mapping New Pathways for Novartis. Darren Weston, Project Leader Pat Majcher, Senior Principal Programmer

CDISC - Mapping New Pathways for Novartis. Darren Weston, Project Leader Pat Majcher, Senior Principal Programmer CDISC - Mapping New Pathways for Novartis Darren Weston, Project Leader Pat Majcher, Senior Principal Programmer Shuhong hong Xie, Senior Statistical Programmer Agenda What was the submission request?

More information

Design and Construct Efficacy Analysis Datasets in Late Phase Oncology Studies

Design and Construct Efficacy Analysis Datasets in Late Phase Oncology Studies PharmaSUG China Design and Construct Efficacy Analysis s in Late Phase Oncology Studies Huadan Li, MSD R&D (China) Co., Ltd., Beijing, China Changhong Shi, MSD R&D (China) Co., Ltd., Beijing, China ABSTRACT

More information

The Standard for the Exchange of Nonclinical Data (SEND): History, Basics, and Comparisons with Clinical Data

The Standard for the Exchange of Nonclinical Data (SEND): History, Basics, and Comparisons with Clinical Data Life Sciences Accelerated R&D Services The Science of Getting Products to Patients Faster The Standard for the Exchange of Nonclinical Data (SEND): History, Basics, and Comparisons with Clinical Data Fred

More information

CFAST Asthma Project. Rhonda Facile. CDISC International Interchange Session 4B: Therapeutic Area Standards in Action November 6, 2013

CFAST Asthma Project. Rhonda Facile. CDISC International Interchange Session 4B: Therapeutic Area Standards in Action November 6, 2013 CFAST Asthma Project Rhonda Facile CDISC International Interchange Session 4B: Therapeutic Area Standards in Action November 6, 2013 1 Asthma Project CFAST Development Principles Asthma Background What

More information

Therapeutic Area Data Standards User Guide for Cardiovascular Studies Version 1.0 (Provisional) Prepared by the CFAST Cardiovascular Team

Therapeutic Area Data Standards User Guide for Cardiovascular Studies Version 1.0 (Provisional) Prepared by the CFAST Cardiovascular Team Therapeutic Area Data Standards User Guide for Cardiovascular Studies Version 1.0 (Provisional) Prepared by the CFAST Cardiovascular Team Notes to Readers This is the provisional version 1.0 of the Therapeutic

More information

Examples: Tables. Descriptive stats with ANOVA, ANCOVA, and t test p values Frequency and percent Correlation coefficients

Examples: Tables. Descriptive stats with ANOVA, ANCOVA, and t test p values Frequency and percent Correlation coefficients Examples: Tables Descriptive stats with ANOVA, ANCOVA, and t test p values Frequency and percent Correlation coefficients Descriptive Statistics Table 1. Body Mass Index using Last Observation Carried

More information

CDISC Public Webinar- Post Traumatic Stress Disorder Therapeutic Area User Guide

CDISC Public Webinar- Post Traumatic Stress Disorder Therapeutic Area User Guide CDISC Public Webinar- Post Traumatic Stress Disorder Therapeutic Area User Guide 26 September 2017 Allyson Gage Cohen Veterans Biosciences Amy Palmer CDISC Kathleen Mellars CDISC Dana Booth - CDISC 1 AGENDA

More information

ADaM Considerations and Content in the TA User Guides. Susan J Kenny, PhD Maximum Likelihood, Inc.

ADaM Considerations and Content in the TA User Guides. Susan J Kenny, PhD Maximum Likelihood, Inc. ADaM Considerations and Content in the TA User Guides Susan J Kenny, PhD Maximum Likelihood, Inc. Topics to Discuss Focus of ADaM content Overview of TAUGs with ADaM content Specific ADaM content in selected

More information

Breast Cancer TAUG Overview and Implementation

Breast Cancer TAUG Overview and Implementation Breast Cancer TAUG Overview and Implementation Anita Umesh, Ph.D. Senior Scientist, Enterprise Informatics Illumina, Inc. Bay Area CDISC User Group 9 December 2015 2014 Illumina, Inc. All rights reserved.

More information

Data Management and CDISC Formatting for Transdermal Patches Lois Lynn, Noven Pharmaceuticals, Inc., Jersey City, NJ

Data Management and CDISC Formatting for Transdermal Patches Lois Lynn, Noven Pharmaceuticals, Inc., Jersey City, NJ PharmaSUG 2018 - Paper MD-05 ABSTRACT Data Management and CDISC Formatting for Transdermal Patches Lois Lynn, Noven Pharmaceuticals, Inc., Jersey City, NJ Transdermal patch use is an alternative delivery

More information

Institute of Medicine Workshop: DIGITAL DATA PRIORITIES FOR CONTINUOUS LEARNING IN HEALTH AND HEALTH CARE

Institute of Medicine Workshop: DIGITAL DATA PRIORITIES FOR CONTINUOUS LEARNING IN HEALTH AND HEALTH CARE Institute of Medicine Workshop: DIGITAL DATA PRIORITIES FOR CONTINUOUS LEARNING IN HEALTH AND HEALTH CARE Data Quality in Clinical Research 23 March 2012 Rebecca D. Kush, PhD President and CEO, CDISC CDISC

More information

CDISC CONTROLLED TERMINOLOGY. Presented by Chris Gemma and Erin Muhlbradt, Ph.D.

CDISC CONTROLLED TERMINOLOGY. Presented by Chris Gemma and Erin Muhlbradt, Ph.D. 1 CDISC CONTROLLED TERMINOLOGY Presented by Chris Gemma and Erin Muhlbradt, Ph.D. CDISC 2018 2 Question & Answer Panelist : Question OR Presentation : Question Examples: 1) What should be supported by

More information

CDISC Controlled Terminology. Presented by Chris Gemma and Erin Muhlbradt, Ph.D.

CDISC Controlled Terminology. Presented by Chris Gemma and Erin Muhlbradt, Ph.D. CDISC Controlled Terminology Presented by Chris Gemma and Erin Muhlbradt, Ph.D. Panelists Erin Muhlbradt, Clincal/Biomedical Information Specialist, MSC Chris Gemma, Project Manager, CDISC 2 Question &

More information

Grading Lab Toxicities using NCI- Common Terminology Criteria for Adverse Events (CTCAE)

Grading Lab Toxicities using NCI- Common Terminology Criteria for Adverse Events (CTCAE) Paper DH03 Grading Lab Toxicities using NCI- Common Terminology Criteria for Adverse Events (CTCAE) Srinivas Veeragoni, BHC Pharmaceuticals Inc., Whippany, USA Ankur Mathur, Bayer Inc., Toronto, Canada

More information

in the ICH Regions Table of Content Annexes to Guideline and 3. Why is Q4B necessary? Q4B Annexes? for Human Use

in the ICH Regions Table of Content Annexes to Guideline and 3. Why is Q4B necessary? Q4B Annexes? for Human Use Frequently Asked Questions Q4B: Evaluation and Recommendation of Pharmacopoeial Texts for Use in the ICH Regions The Q4B Expert Working Group developed a set of frequently asked questions to help users

More information

PharmaSUG 2018 Paper AD-02

PharmaSUG 2018 Paper AD-02 PharmaSUG 2018 Paper AD-02 Derivations of Response Status from SDTM Domains using RECIST 1.1 Christine Teng, Merck Research Laboratories, Merck & Co., Inc., Rahway, NJ USA Pang Lei, Merck Research Laboratories,

More information

Study Endpoint Considerations: Final PRO Guidance and Beyond

Study Endpoint Considerations: Final PRO Guidance and Beyond Study Endpoint Considerations: Final PRO Guidance and Beyond Laurie Burke Associate Director for Study Endpoints and Labeling OND/CDER/FDA Presented at: FIRST ANNUAL PATIENT REPORTED OUTCOMES (PRO) CONSORTIUM

More information

Graph Display of Patient Profile Using SAS

Graph Display of Patient Profile Using SAS PharmaSUG 2018 - Paper DV-17 Graph Display of Patient Profile Using SAS Yanwei Han, Seqirus USA Inc., Cambridge, MA Hongyu Liu, Seqirus USA Inc., Cambridge, MA ABSTRACT We usually create patient profile

More information

Authors and Co-Authors,

Authors and Co-Authors, Neurology Journals Authorship Agreement Authors and Co-Authors, To make authorship and sponsorship transparent to all readers, Neurology has changed its policy to include as Authors those who have made

More information

Scientific Working Group on Digital Evidence

Scientific Working Group on Digital Evidence Disclaimer: As a condition to the use of this document and the information contained therein, the SWGDE requests notification by e-mail before or contemporaneous to the introduction of this document, or

More information

A critical appraisal of: Canadian guideline fysisk aktivitet using the AGREE II Instrument

A critical appraisal of: Canadian guideline fysisk aktivitet using the AGREE II Instrument A critical appraisal of: Canadian guideline fysisk aktivitet using the AGREE II Instrument Created with the AGREE II Online Guideline Appraisal Tool. No endorsement of the content of this document by the

More information

CDISC SHARE. CDISC Shared Health and Research Electronic Library Pilot Report. Date: 19 January 2010 Version: 1.0 CDISC, 2010

CDISC SHARE. CDISC Shared Health and Research Electronic Library Pilot Report. Date: 19 January 2010 Version: 1.0 CDISC, 2010 CDISC SHARE CDISC Shared Health and Research Electronic Library Pilot Report Date: 19 January 2010 Version: 1.0 CDISC, 2010 Page 1 of 28 Document History Issue Author Date Description 0.1 Pilot Team 9

More information

British Columbia Data Standards

British Columbia Data Standards British Columbia Data Standards Minimum Immunization Data Set Interoperability Guide Version: 1.0 October 23, 2017 Sponsors PHSA: Jill Reedijk Canada Health Infoway DOCUMENT CONTROL DOCUMENT HISTORY Version

More information

Global Harmonization Task Force SG3 Comments and Recommendations ISO/DIS 9001: 2000 and ISO/DIS 9000: 2000 And Revision of ISO and 13488

Global Harmonization Task Force SG3 Comments and Recommendations ISO/DIS 9001: 2000 and ISO/DIS 9000: 2000 And Revision of ISO and 13488 Page 1 of 6 Global Harmonization Task Force SG3 ISO/DIS 9001: 2000 and ISO/DIS 9000: 2000 And Revision of ISO 13485 and 13488 GENERAL COMMENTS The Global Harmonization Task Force Study Group Three (GHTF

More information

BEST PRACTICES FOR IMPLEMENTATION AND ANALYSIS OF PAIN SCALE PATIENT REPORTED OUTCOMES IN CLINICAL TRIALS

BEST PRACTICES FOR IMPLEMENTATION AND ANALYSIS OF PAIN SCALE PATIENT REPORTED OUTCOMES IN CLINICAL TRIALS BEST PRACTICES FOR IMPLEMENTATION AND ANALYSIS OF PAIN SCALE PATIENT REPORTED OUTCOMES IN CLINICAL TRIALS Nan Shao, Ph.D. Director, Biostatistics Premier Research Group, Limited and Mark Jaros, Ph.D. Senior

More information

CDISC Public Webinar- Huntington's Disease Therapeutic Area User Guide

CDISC Public Webinar- Huntington's Disease Therapeutic Area User Guide CDISC Public Webinar- Huntington's Disease Therapeutic Area User Guide 12 September 2017 Jon Neville CDISC Daniel Olson- Critical Path Institute (C-Path) 1 AGENDA Project Background Introduction to Huntington's

More information

2017 OPTIONS FOR INDIVIDUAL MEASURES: REGISTRY ONLY. MEASURE TYPE: Process

2017 OPTIONS FOR INDIVIDUAL MEASURES: REGISTRY ONLY. MEASURE TYPE: Process Measure #109: Osteoarthritis (OA): Function and Pain Assessment National Quality Strategy Domain: Person and Caregiver-Centered Experience and Outcomes 2017 OPTIONS FOR INDIVIDUAL MEASURES: REGISTRY ONLY

More information

ADaM Grouping: Groups, Categories, and Criteria. Which Way Should I Go?

ADaM Grouping: Groups, Categories, and Criteria. Which Way Should I Go? ABSTRACT PharmaSUG 2017 - Paper DS17 ADaM Grouping: Groups, Categories, and Criteria. Which Way Should I Go? Jack Shostak, Duke Clinical Research Institute ADaM has variables that allow you to cluster,

More information

Request for Proposals

Request for Proposals Background The U.S. Preventive Services Task Force (USPSTF or Task Force) is an independent, volunteer panel of national experts in prevention and evidence-based medicine. Since its inception in 1984,

More information

Critical Path Institute Coalition Against Major Diseases (CAMD) Alzheimer s Clinical Trial Database

Critical Path Institute Coalition Against Major Diseases (CAMD) Alzheimer s Clinical Trial Database Critical Path Institute Coalition Against Major Diseases (CAMD) Alzheimer s Clinical Trial Database Dr. Carolyn Compton, M.D., Ph.D. Chief Executive Officer Critical Path Institute 1 What We Do DEVELOP

More information

2019 COLLECTION TYPE: MIPS CLINICAL QUALITY MEASURES (CQMS) MEASURE TYPE: Outcome High Priority

2019 COLLECTION TYPE: MIPS CLINICAL QUALITY MEASURES (CQMS) MEASURE TYPE: Outcome High Priority Quality ID #355: Unplanned Reoperation within the 30 Day Postoperative Period National Quality Strategy Domain: Patient Safety Meaningful Measure Area: Admissions and Readmissions to Hospitals 2019 COLLECTION

More information

Standards for Analyzable Submission Datasets for Directed Safety Analyses

Standards for Analyzable Submission Datasets for Directed Safety Analyses Standards for Analyzable Submission Datasets for Directed Safety Analyses Michael Nessly Director, Clinical Biostatistics Merck Research Labs CDISC Analysis Dataset Models Team (ADaM) nesslym@merck.com

More information

How to - Trial Summary Parameter. CJUG SDTM Team : LISaS

How to - Trial Summary Parameter. CJUG SDTM Team : LISaS How to - Trial Summary Parameter CJUG SDTM Team : LISaS 2013-11-08 Preconditions for the Discussion CDISC Controlled Terminology: As of 2013-10-04 SDTM IG: v3.1.3 or v3.1.2 CDISC Protocol Representation

More information

ISA 540, Auditing Accounting Estimates, Including Fair Value Accounting Estimates, and Related Disclosures Issues and Task Force Recommendations

ISA 540, Auditing Accounting Estimates, Including Fair Value Accounting Estimates, and Related Disclosures Issues and Task Force Recommendations Agenda Item 1-A ISA 540, Auditing Accounting Estimates, Including Fair Value Accounting Estimates, and Related Disclosures Issues and Task Force Recommendations Introduction 1. Since the September 2016

More information

IAASB Main Agenda (March 2005) Page Agenda Item. DRAFT EXPLANATORY MEMORANDUM ISA 701 and ISA 702 Exposure Drafts February 2005

IAASB Main Agenda (March 2005) Page Agenda Item. DRAFT EXPLANATORY MEMORANDUM ISA 701 and ISA 702 Exposure Drafts February 2005 IAASB Main Agenda (March 2005) Page 2005 579 Agenda Item 13-F DRAFT EXPLANATORY MEMORANDUM ISA 701 and ISA 702 Exposure Drafts February 2005 Introduction This memorandum provides some background to, and

More information

Clinical Review Report (Sample)

Clinical Review Report (Sample) CADTH COMMON DRUG REVIEW Clinical Review Report (Sample) GENERIC DRUG NAME (BRAND NAME) (Manufacturer) Indication: Text Disclaimer: The information in this document is intended to help Canadian health

More information

DENOMINATOR: All patients aged 18 years and older with a diagnosis of coronary artery disease seen within a 12 month period

DENOMINATOR: All patients aged 18 years and older with a diagnosis of coronary artery disease seen within a 12 month period Quality ID #6 (NQF 0067): Coronary Artery Disease (CAD): Antiplatelet Therapy National Quality Strategy Domain: Effective Clinical Care Meaningful Measure Area: Management of Chronic Conditions 2019 COLLECTION

More information

Cancer Chemotherapy in Clinical Practice

Cancer Chemotherapy in Clinical Practice Cancer Chemotherapy in Clinical Practice Cancer Chemotherapy in Clinical Practice Terry Priestman Terry Priestman, MD, FRCP, FRCR New Cross Hospital Wolverhampton UK British Library Cataloguing in Publication

More information

*NOTE: When submitting CPT code and 99239, it is recommended the measure be submitted each time the code is submitted for hospital discharge.

*NOTE: When submitting CPT code and 99239, it is recommended the measure be submitted each time the code is submitted for hospital discharge. Quality ID #5 (NQF 0081): Heart Failure (HF): Angiotensin-Converting Enzyme (ACE) Inhibitor or Angiotensin Receptor Blocker (ARB) Therapy for Left Ventricular Systolic Dysfunction (LVSD) National Quality

More information

Cochrane Breast Cancer Group

Cochrane Breast Cancer Group Cochrane Breast Cancer Group Version and date: V3.2, September 2013 Intervention Cochrane Protocol checklist for authors This checklist is designed to help you (the authors) complete your Cochrane Protocol.

More information

Measure #355: Unplanned Reoperation within the 30 Day Postoperative Period National Quality Strategy Domain: Patient Safety

Measure #355: Unplanned Reoperation within the 30 Day Postoperative Period National Quality Strategy Domain: Patient Safety Measure #355: Unplanned Reoperation within the 30 Day Postoperative Period National Quality Strategy Domain: Patient Safety 2017 OPTIONS FOR INDIVIDUAL MEASURES: REGISTRY ONLY MEASURE TYPE: Outcome DESCRIPTION:

More information

ADaM Tips for Exposure Summary

ADaM Tips for Exposure Summary ABSTRACT PharmaSUG China 2016 Paper 84 ADaM Tips for Exposure Summary Kriss Harris, SAS Specialists Limited, Hertfordshire, United Kingdom Have you ever created the Analysis Dataset for the Exposure Summary

More information

SDTM, Implementation Guide, and User Guide Updates

SDTM, Implementation Guide, and User Guide Updates Accenture Life Sciences Rethink Reshape Restructure for better health outcomes. Octagon is Now Part of Accenture SDTM, Implementation Guide, and User Guide Updates Fred Wood July 2013 Agenda Model, IG,

More information

Standards for the reporting of new Cochrane Intervention Reviews

Standards for the reporting of new Cochrane Intervention Reviews Methodological Expectations of Cochrane Intervention Reviews (MECIR) Standards for the reporting of new Cochrane Intervention Reviews 24 September 2012 Preface The standards below summarize proposed attributes

More information

Row same as start date 513) Examples for Treatments Major Issue Closed

Row same as start date 513) Examples for Treatments Major Issue Closed 1 Please add a dot in line 1087, behind "membrane" Appendix E Typo Updated as requested 2 Please suggest to add abbreviation "NAC" and its definition (see line 1142) Appendix C Minor Issue Appendix C updated

More information

WELSH INFORMATION STANDARDS BOARD

WELSH INFORMATION STANDARDS BOARD WELSH INFORMATION STANDARDS BOARD DSC Notice: DSCN 2018 / 06 Date of Issue: 8 th August 2018 Welsh Health Circular / Official Letter: (2015) 053 Subject: CT Maturity Matrix Sponsor: Chris Newbrook, Head

More information

TRANSLATION. Montreal, April 11, 2011

TRANSLATION. Montreal, April 11, 2011 TRANSLATION Montreal, April 11, 2011 Technical Director International Auditing and Assurance Standards Board 545 Fifth Avenue, 14 th Floor New York, New York 10017 USA Dear Madam/Sir: Please find enclosed

More information

ALL PRINCIPAL INVESTIGATORS/NURSES/DATA MANAGERS RE: PROTOCOL GOG-0233 ACRIN 6671, REVISION # 9 & #10

ALL PRINCIPAL INVESTIGATORS/NURSES/DATA MANAGERS RE: PROTOCOL GOG-0233 ACRIN 6671, REVISION # 9 & #10 TO: FROM: ALL PRINCIPAL INVESTIGATORS/NURSES/DATA MANAGERS LEAH MADDEN PROTOCOL SECTION DATE: JUNE 27, 2011 RE: PROTOCOL GOG-0233 ACRIN 6671, REVISION # 9 & #10 Protocol Title: Utility of Preoperative

More information

UPDATE ON PREMARKET TOBACCO PRODUCT AUTHORIZATION PATHWAY

UPDATE ON PREMARKET TOBACCO PRODUCT AUTHORIZATION PATHWAY UPDATE ON PREMARKET TOBACCO PRODUCT AUTHORIZATION PATHWAY Presented by Ii-Lun Chen, M.D Director Division of Individual Health Science Office of Science, CTP, FDA Disclaimer: This is not a formal dissemination

More information

2017 OPTIONS FOR INDIVIDUAL MEASURES: REGISTRY ONLY. MEASURE TYPE: Process

2017 OPTIONS FOR INDIVIDUAL MEASURES: REGISTRY ONLY. MEASURE TYPE: Process Measure #143 (NQF 0384): Oncology: Medical and Radiation Pain Intensity Quantified National Quality Strategy Domain: Person and Caregiver-Centered Experience and Outcomes 2017 OPTIONS FOR INDIVIDUAL MEASURES:

More information

EFSA PRE-SUBMISSION GUIDANCE FOR APPLICANTS INTENDING TO SUBMIT APPLICATIONS FOR AUTHORISATION OF HEALTH CLAIMS MADE ON FOODS

EFSA PRE-SUBMISSION GUIDANCE FOR APPLICANTS INTENDING TO SUBMIT APPLICATIONS FOR AUTHORISATION OF HEALTH CLAIMS MADE ON FOODS EFSA PRE-SUBMISSION GUIDANCE FOR APPLICANTS INTENDING TO SUBMIT APPLICATIONS FOR AUTHORISATION OF HEALTH CLAIMS MADE ON FOODS Last updated (Rev.): 21 December 2007 Publication Date: 14 March 2007 NOTES

More information

A SAS sy Study of ediary Data

A SAS sy Study of ediary Data A SAS sy Study of ediary Data ABSTRACT PharmaSUG 2017 - Paper BB14 A SAS sy Study of ediary Data Amie Bissonett, inventiv Health Clinical, Minneapolis, MN Many sponsors are using electronic diaries (ediaries)

More information

COGNITIVE FUNCTION. PROMIS Pediatric Item Bank v1.0 Cognitive Function PROMIS Pediatric Short Form v1.0 Cognitive Function 7a

COGNITIVE FUNCTION. PROMIS Pediatric Item Bank v1.0 Cognitive Function PROMIS Pediatric Short Form v1.0 Cognitive Function 7a COGNITIVE FUNCTION A brief guide to the PROMIS Cognitive Function instruments: ADULT PEDIATRIC PARENT PROXY PROMIS Item Bank v1.0 Applied Cognition - Abilities* PROMIS Item Bank v1.0 Applied Cognition

More information

Using CDISC Models for the Analysis of Safety Data

Using CDISC Models for the Analysis of Safety Data Paper RA02 Using CDISC Models for the Analysis of Safety Data Susan J. Kenny, Inspire Pharmaceuticals Inc. Research Triangle Park, NC, USA Edward D. Helton, SAS Institute, Cary, NC, USA ABSTRACT The collection

More information

EVIDENCE IN BRIEF OVERALL CLINICAL BENEFIT

EVIDENCE IN BRIEF OVERALL CLINICAL BENEFIT differ and that they each has a unique mechanism of action. As such perc considered that it would be important for clinicians and patients to be able to choose either drug as a first-line treatment option.

More information

DRAFT (Final) Concept Paper On choosing appropriate estimands and defining sensitivity analyses in confirmatory clinical trials

DRAFT (Final) Concept Paper On choosing appropriate estimands and defining sensitivity analyses in confirmatory clinical trials DRAFT (Final) Concept Paper On choosing appropriate estimands and defining sensitivity analyses in confirmatory clinical trials EFSPI Comments Page General Priority (H/M/L) Comment The concept to develop

More information

2019 COLLECTION TYPE: MIPS CLINICAL QUALITY MEASURES (CQMS) MEASURE TYPE: Process

2019 COLLECTION TYPE: MIPS CLINICAL QUALITY MEASURES (CQMS) MEASURE TYPE: Process Quality ID #249 (NQF 1854): Barrett s Esophagus National Quality Strategy Domain: Effective Clinical Care Meaningful Measure Area: Transfer of Health Information and Interoperability 2019 COLLECTION TYPE:

More information

Immediate-release Hydrocodone/Acetaminophen M Abbreviated Clinical Study Report R&D/08/1020

Immediate-release Hydrocodone/Acetaminophen M Abbreviated Clinical Study Report R&D/08/1020 2.0 Synopsis Abbott Laboratories Individual Study Table Referring to Part of Dossier: (For National Authority Use Only) Name of Study Drug: Volume: Hydrocodone Bitartrate- Acetaminophen (NORCO ) Name of

More information

OVERALL CLINICAL BENEFIT

OVERALL CLINICAL BENEFIT noted that there are case reports of a rebound effect upon discontinuation of ruxolitinib (Tefferi 2012), although this was not observed in either the COMFORT I or COMFORT II studies. Therefore, perc considered

More information

Understanding test accuracy research: a test consequence graphic

Understanding test accuracy research: a test consequence graphic Whiting and Davenport Diagnostic and Prognostic Research (2018) 2:2 DOI 10.1186/s41512-017-0023-0 Diagnostic and Prognostic Research METHODOLOGY Understanding test accuracy research: a test consequence

More information

FURNITURE TERMS / POLICIES. TERMS OF FURNITURE SALE [agreement is required with all orders] FURNITURE ORDERS

FURNITURE TERMS / POLICIES. TERMS OF FURNITURE SALE [agreement is required with all orders] FURNITURE ORDERS FURNITURE TERMS / POLICIES TERMS OF FURNITURE SALE [agreement is required with all orders] FURNITURE ORDERS Weaver Furniture Sales, Inc. ( WFS ) offers you a variety of ways to place orders. You can send

More information

PRSB e-discharge summary phase 2 Medications and medical devices information model

PRSB e-discharge summary phase 2 Medications and medical devices information model PRSB e-discharge summary phase 2 Medications and medical devices information model Purpose This paper provides an information model for medications and medical devices. It is based on the discharge summary

More information

Where Is the Link Broken Another Look at SDTM Oncology Tumor Packages

Where Is the Link Broken Another Look at SDTM Oncology Tumor Packages PharmaSUG 2017 Paper DS07 Where Is the Link Broken Another Look at SDTM Oncology Tumor Packages ABSTRACT Hong WANG, Boehringer Ingelheim, Ridgefield, CT Ke XIAO, Boehringer Ingelheim, Ridgefield, CT CDISC

More information

Mental health practitioners working in medicine represent the vanguard

Mental health practitioners working in medicine represent the vanguard Series Foreword Mental health practitioners working in medicine represent the vanguard of psychological practice. As scientific discovery and advancement in medicine has rapidly evolved in recent decades,

More information

Measure #110 (NQF 0041): Preventive Care and Screening: Influenza Immunization National Quality Strategy Domain: Community/Population Health

Measure #110 (NQF 0041): Preventive Care and Screening: Influenza Immunization National Quality Strategy Domain: Community/Population Health Measure #110 (NQF 0041): Preventive Care and Screening: Influenza Immunization National Quality Strategy Domain: Community/Population Health 2017 OPTIONS FOR INDIVIDUAL MEASURES: REGISTRY ONLY MEASURE

More information

HOW IS PACE TO BE USED

HOW IS PACE TO BE USED Introduction and overview of the pace monitor what is THE PACE MONITOR The PACE Monitor is a comprehensive program for the screening, in-depth assessment and the evaluation of the progress and change of

More information

Broad and clinically important benefits beyond the initial registrational endpoints are now reported.

Broad and clinically important benefits beyond the initial registrational endpoints are now reported. Biohaven Announces Robust Clinical Data with Single Dose Rimegepant That Defines Acute and Durable Benefits to Patients: The First Oral CGRP Receptor Antagonist to Deliver Positive Data on Pain Freedom

More information

GOOD PHARMACOPOEIAL PRACTICES

GOOD PHARMACOPOEIAL PRACTICES May 2013 RESTRICTED GOOD PHARMACOPOEIAL PRACTICES CONCEPT PAPER ON PURPOSE AND BENEFITS (MAY 2013) DRAFT FOR COMMENT Please address any comments on this proposal by 12 July 2013 to Dr S. Kopp, Medicines

More information

CONSORT 2010 checklist of information to include when reporting a randomised trial*

CONSORT 2010 checklist of information to include when reporting a randomised trial* CONSORT 2010 checklist of information to include when reporting a randomised trial* Section/Topic Title and abstract Introduction Background and objectives Item No Checklist item 1a Identification as a

More information

IAF Mandatory Document. Requirements for the Migration to ISO 45001:2018 from OHSAS 18001:2007 (IAF MD 21:2018)

IAF Mandatory Document. Requirements for the Migration to ISO 45001:2018 from OHSAS 18001:2007 (IAF MD 21:2018) IAF Mandatory Document Requirements for the Migration to ISO 45001:2018 from OHSAS 18001:2007 Issue 1 (IAF MD 21:2018) Issue 1 Requirements for the Migration to Page 2 of 12 The (IAF) facilitates trade

More information

2018 OPTIONS FOR INDIVIDUAL MEASURES: REGISTRY ONLY. MEASURE TYPE: Process

2018 OPTIONS FOR INDIVIDUAL MEASURES: REGISTRY ONLY. MEASURE TYPE: Process Quality ID #283: Dementia Associated Behavioral and Psychiatric Symptoms Screening and Management National Quality Strategy Domain: Effective Clinical Care 2018 OPTIONS FOR INDIVIDUAL MEASURES: REGISTRY

More information